-
Featured Authors
-
Archives
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Author Archive: Tracy Cooley
Tracy serves as the Director of Events Communications and handles all communications for BIO’s events and emerging company policy issues. She loves blogging and podcasting on all things biotech and believes in the great potential of the industry, looking for every opportunity to spread the message far and wide. Nearly everyone in her family is a golfer, and as such, she has what many people have called a “natural” swing. Sometimes she even hits the ball. Tracy just finished her ninth marathon, and has nearly mastered the skill of one-foot-in-front-of-the-other (usually, sometimes the laces get in the way). The joy of her life is her five-year-old daughter Josephine.
Latest Posts
Gates Foundation and Grand Challenge Partners Announce New Investments in Breakthrough Science
At an event in Seattle today, the Bill & Melinda Gates Foundation and a group of international partners announced three new initiatives aimed at encouraging breakthroughs in science. The event celebrates a decade of progress since the Gates Foundation’s launch of the initial Grand Challenges in Global Health initiative, which was created to catalyze scientific and technological innovation to achieve major breakthroughs in global health. The three new initiatives include: • All Children Thriving – Read More >
New PhRMA report: Nearly 800 Cancer Medicines in Development
A new report from the Pharmaceutical Research and Manufacturers of America (PhRMA) shows that biopharma companies are currently developing nearly 800 new medicines and vaccines for cancer. “In recent decades, we have seen great progress in developing effective cancer treatments that help extend lives, improve quality of life and increase productivity,” said PhRMA President and CEO John J. Castellani. “Continued research has expanded our knowledge of how cancer develops and how to target medicines for Read More >
Washington Post: Why Extremely Expensive Drugs Are Often Worth the Cost
Jason Millman highlights a new study published in Health Affairs showing specialty drugs often provide ‘substantially much higher health benefits than the traditional drugs.’ “Our study suggests that although specialty drugs often have higher costs than traditional drugs, they also tend to confer greater benefits and hence may still offer reasonable value for money,” wrote the researchers at the Boston-based Center for Value and Risk in Health. The study authors judged the drugs’ performance by Read More >
Health Affairs: 5 Myths about Cancer Care in America
In the latest issue of Health Affairs, Dana Goldman of the University of Southern California in Los Angeles and Tomas Philipson at the University of Chicago – two of the nation’s leading economists – debunk the most common misconceptions about cancer treatment. They argue that evidence shows that patients value these treatments more highly than what is illustrated through traditional cost-effectiveness analysis. Furthermore, they assert coverage policies that place an undue burden on patients are Read More >
Cancer drugs save and extend lives
This week, CBS aired a misleading segment on the cost of innovative cancer therapies. BIO immediately responded by pointing out that the segment completely ignored the value created by these drugs for patients and the healthcare system. “Cancer patients today are able to live longer and enjoy a higher quality of life than ever before thanks to medicines made by biopharmaceutical research companies,” said Jim Greenwood, BIO President and CEO. “Advances in cancer treatment are Read More >
